OncoMatch/Clinical Trials/NCT07284849
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Is NCT07284849 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including INCA33890 and Bevacizumab for crc (colorectal cancer).
Treatment: INCA33890 · Bevacizumab · FOLFOX — The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Excluded: BRAF V600E mutation
BRAF V600E mutation per historical data in the medical record.
Excluded: MMR deficient mismatch repair
dMMR per historical data in the medical record.
Excluded: MSI high
MSI-H per historical data in the medical record.
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years.
Cannot have received: anti-PD-L1 therapy
Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years.
Cannot have received: checkpoint inhibitor
Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years.
Lab requirements
Blood counts
Adequate organ function determined by laboratory results.
Kidney function
Adequate organ function determined by laboratory results.
Liver function
Adequate organ function determined by laboratory results.
Adequate organ function determined by laboratory results.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Arizona Cancer Center · Tucson, Arizona
- Roche Tissue Diagnostics, Companion Diagnostics · Tucson, Arizona
- Toi Clinical Research · Cerritos, California
- Los Angeles Cancer Network · Fountain Valley, California
- Providence Medical Foundation · Fullerton, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07284849 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with BRAF alterations eligible?
No. BRAF V600E mutation is an exclusion criterion.
Are patients with MMR alterations eligible?
No. MMR deficient mismatch repair is an exclusion criterion.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages